Industry News

Baxter First patients receiving NUMETA G13E IV nutrition therapy located in Sweden. COPENHAGEN, Denmark---- Baxter International Inc., a global leader in PN therapy, announced the European launch of NUMETA G13E 300 mL, the only ready-to-use parenteral nutrition product available to treat preterm infants who are at high risk for..."/>
Baxter Launches NUMETA G13E in Europe: Only Ready-to-Use IV Nutrition for Vulnerable Preterm Newborns at Risk for Malnutrition
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who are at intermediate risk for open-heart surgery. "This expanded intermediate-risk indication allows..."/>
Edwards Sapien 3 Transcatheter Heart Valve Receives Expanded Indication In Europe
Seattle Genetics’ Second Clinical ADC Program Focused on AML-. -Preclinical Data Showing Potent Anti-Leukemic Activity of SGN-CD123A Presented at the 2015 American Society of Hematology Annual Meeting-. BOTHELL, Wash.---- Seattle Genetics, Inc. today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD123A for patients with relapsed or refractory acute myeloid leukemia."/>
Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Canopy Growth Corporation has entered into an agreement with Delivra Inc. to supply Canopy Growth's operating subsidiaries, including Tweed Inc. and Bedrocan Canada Inc., with cannabis-infused topical product formulations. Topical cannabis products have proven market demand but have yet to be created for the legal medical cannabis market in Canada. By teaming with Delivra, Tweed will be able to offer customers a unique product suite, produced to..."/>
Canopy Growth and Delivra Partner to Offer Innovative Therapeutic Cannabis Products
Exact Sciences on Friday announced the award of restricted stock units covering a total of 24,119 shares of its common stock under its inducement grant programme. Under the NASDAQ Marketplace Rule 5635 (c), the company said the restricted stock units to 18 new non-executive employees as an inducement material into entering into employment. The company said the restricted stock unit awards vest in four equal annual installments beginning on..."/>
Exact Sciences reports grant of inducement restricted stock units to 18 new appointments
Depomed, Inc., with beneficial ownership of approximately 9.8% of Depomed's outstanding shares, today announced it has delivered an open letter to Depomed shareholders. Starboard also announced that as of this past Friday it has delivered to Depomed more than the required consents to call a Special Meeting of Depomed shareholders and has set November 15, 2016 as the date for the Special..."/>
Starboard Delivers Special Meeting Request to Depomed and Issues Letter to Depomed Shareholders
Molina Healthcare said on Friday that it has completed the exchange offer of its privately placed 5.375% senior notes due 2022 with registered 5.375% senior notes due 2022.. The company has completed its offer to exchange up to USD700m aggregate principal amount of its 5.375% senior notes due 2022 and the note guarantees associated therewith exempt from the registration requirements of the Securities Act of 1933 in a private placement with up to an..."/>
Molina Healthcare announces completion and expiry of exchange offer
ICON buys Clinical Research Management for undisclosed fee
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic development pipeline, today announces a new five-year strategic manufacturing services agreement under which PCT will produce SPEAR ® T-cell therapies for Adaptimmune Therapeutics plc. PCT, through dedicated, specialized staff and facilities, will produce the SPEAR ® T-cell..."/>
Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it has entered into a new five-year strategic manufacturing agreement with PCT, a Caladrius company, a subsidiary of Caladrius Biosciences for the supply of Adaptimmune’ s SPEAR ® T-cell therapies. Under the contract, Adaptimmune will benefit from exclusive access to an EU and FDA compliant manufacturing unit at PCT as well as..."/>
Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization
Cytokinetics, Inc. today announced that additional results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented in a Rapid Fire Abstract Session at the 20 th Annual Heart Failure Society of America Scientific Meeting in Orlando, FL. The results presented show that omecamtiv mecarbil may improve symptoms in patients with moderate to severe heart failure symptoms versus..."/>
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting
Madrigal Pharmaceuticals, Inc. and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the discovery, development and commercialization by Tarveda of products based on Madrigal’ s HSP90 Drug Conjugate program, including the lead clinical candidate, PEN-866."/>
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform
GeneNews Limited today announced it has entered into a partnership agreement with NueHealth, LLC, a privately owned company that delivers value-based healthcare solutions and connects patients directly to physicians through integrated provider networks, or IPNs.. Patients who access healthcare through NueHealth's provider networks will now be able to take advantage of three different screening tests- ColonSentry ®, earlyCDT ®- Lung and Prostate..."/>
GeneNews and NueHealth Announce Partnership in Early Cancer Diagnostics
Centene Corporation, announced today a public-private partnership between the Atlanta VA Medical Center, DeKalb Medical's Mobile Mammograms, and HNFS through the Department of Veterans Affairs' Veterans' Choice Program. This newly-formed program will expedite veteran care through the Veterans Choice program by providing mammograms at the Mobile Mammogram..."/>
HNFS Offers Mobile Mammogram To Vets Of Atlanta
Novocure announced today that CNS Oncology published Tumor Treating Fields treatment planning and patient follow-up guidelines, providing a standardized resource for the use of the NovoTAL System..."/>
CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma
Alere, Inc. as well as from TechLab’ s founders Dr. David Lyerly, who will remain with the Company and maintain a minority investment."/>
Pharos Capital Acquires TechLab, Leading Developer of Gastrointestinal Disease Diagnostics
FONAR Corporation. 22% Increase of Fiscal 2016 Diluted Net Income per Common Share available to Common Shareholders to $2.38, versus prior year 22% Increase of Fiscal 2016 Net Income to $18.8 million, versus prior year 11% Increase of Fiscal 2016 Income from Operations to $14.4 million, versus prior year 6% Increase of Fiscal 2016 Net Revenues to $73.4 million, versus prior year Diluted Net Income per Common Share available to Common Shareholders for the..."/>
FONAR Announces Fiscal 2016 Year End Earnings
Pediapharm Inc. is pleased to announce it has signed an exclusive licensing agreement with a company owned by Mr."/>
Pediapharm Announces Global Exclusive Licensing Agreement for Relaxa(R), an Established Canadian Product With Existing Revenues
Molina Healthcare reported on Friday that it has appointed Britt Travis as new vice president of its Medicare sales. In the new sales position, Travis will lead and oversee the company's sales operations, its distribution strategy and execution as well as its channel development and management in the states in which its offers its Medicare products. Travis previously served as vice president of distribution and sales at Highmark, a medicare..."/>
Molina Healthcare appoints Britt Travis as VP of Medicare Sales
Ligand Pharmaceuticals Incorporated reported on Friday that it has signed an OmniAb worldwide license agreement with Menlo Park, CA-based TeneoBio, a development stage biotechnology company. This license agreement allows TeneoBio to use Ligand's OmniFlic technology from the OmniAb platform to discover fully human bispecific antibodies to be developed for the treatment of various diseases, with an initial focus on therapeutics for cancer,..."/>
Ligand declares OmniAb License Agreement with TeneoBio Inc
Curis said on Friday that its board of directors' independent compensation committee approved the grant of inducement stock options to purchase a total of 521,000 shares of its common stock to six new employees. The company added that each of the inducement grant has an exercise price per share equal to the closing price of its common stock on 12 September 2016, the date of grant. Subject to the new employee's continued service with the company through the..."/>
Curis awards inducement stock options to six new employees under NASDAQ Listing Rule 5635(c)(4)
AMN Healthcare Services Inc., Healthways Inc., MEDNAX Inc., and HEALTHSOUTH Corp.. These companies belong to the Healthcare sector which finished narrowly mixed in afternoon trading on Friday, September 16, 2016."/>
Research Reports Initiation on Specialized Health Services Stocks -- AMN Healthcare Services, Healthways, MEDNAX, and HEALTHSOUTH
NuVasive, Inc., a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced it has received FDA 510 clearance for the Company's market-leading MAGEC ® system to be surgically implanted using its Reline ® posterior fixation system for treating patients with severe spinal deformity conditions. The Company's MAGEC system is the only magnetically controlled..."/>
NuVasive Receives FDA 510(k) Clearance Reinforcing Comprehensive Portfolio Supporting Pediatric, Adolescent and Adult Spinal Deformity Patients

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology660 Articles
Consumer Discretionary627 Articles
Financials404 Articles
Industrials389 Articles
Health Care366 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.